U.S. Jury Rules Takeda to Pay $885M in Damages
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
A U.S. jury on Monday determined that Takeda Pharmaceutical caused pharmacies, insurers, retailers, and others to sustain roughly $885M in damages by postponing the release of a generic version of its anti-constipation drug Amitiza through anticompetitive means, Reuters' Nate Raymond reports.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.150
Low
18.00
Averages
18.00
High
18.00
Current: 16.150
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Takeda Pharmaceutical Shares Enter Oversold Territory
- Oversold Signal: Takeda Pharmaceutical (TAK) shares hit an RSI of 25.9 on Friday, indicating an oversold condition as the stock traded as low as $16.07 per share, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to seek entry points.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 72.1, TAK's low RSI could attract bullish investors, indicating potential for a market sentiment reversal and paving the way for future price rebounds.
- Historical Performance Analysis: TAK's 52-week low is $12.99 and high is $18.895, with the last trade at $16.25, demonstrating relative stability within its trading range, which may appeal to value-seeking buyers.
- Investor Sentiment: Despite the current oversold status, investors should carefully assess market sentiment and technical indicators to avoid making impulsive decisions in an uncertain market environment.
See More
Innovent's IBI363 Shows Survival Benefits in Lung Cancer Treatment
- Clinical Data Update: At the 2026 ASCO Annual Meeting, Innovent presented updated clinical data for its PD-1/IL-2α bispecific fusion protein IBI363, demonstrating a favorable long-term safety profile in immunotherapy-resistant non-small cell lung cancer (NSCLC), reinforcing its competitive edge in this area.
- Significant Survival Improvement: Among 67 squamous NSCLC patients without known EGFR mutations, the 3 mg/kg Q3W dose group achieved a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months, with a 24-month OS rate of 47.8%, highlighting IBI363's substantial survival advantage.
- Impact of Smoking History: In 58 EGFR wild-type adenocarcinoma patients, those with a smoking history had a median OS of 23.4 months, indicating that smoking history may significantly influence the efficacy of IBI363 in immunotherapy-resistant adenocarcinoma, further emphasizing its clinical potential.
- Favorable Safety Profile: In a long-term follow-up of 136 patients, IBI363 exhibited a treatment-emergent adverse event rate of 48.5%, primarily manageable arthralgia and anemia, with no new safety signals observed, indicating its viability for clinical use.
See More
Takeda Pharmaceutical Loses Antitrust Case Verdict
- Antitrust Verdict: A jury in the U.S. District Court for Massachusetts ruled against Takeda Pharmaceutical in the AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs approximately $884.9 million in single damages, highlighting the legal risks associated with drug patents and market competition.
- Treble Damages: Under U.S. antitrust law, the awarded damages are subject to automatic trebling, potentially increasing Takeda's liability to nearly $2.655 billion, which could severely impact its financial health and future cash flows.
- Post-Trial Actions: Takeda plans to vigorously pursue post-trial motions and an appeal, asserting that evidentiary and legal errors occurred during the trial, a strategy that may affect its market reputation and investor confidence.
- Financial Impact Assessment: The company is assessing the provision amount to be recognized in its full-year 2025 consolidated financial statements related to this matter and intends to revise and re-file its financial reports, although it does not expect a significant impact on its core financial results for 2025.
See More
Takeda Pharmaceutical Found Guilty of Delaying Generic Drug
- Anti-Competitive Ruling: A federal jury in Boston found Takeda Pharmaceutical (TAK) guilty of entering a reverse payment arrangement with generic drugmaker Par Pharmaceutical, resulting in health plans and pharmacies like CVS overpaying hundreds of millions, highlighting the direct consumer impact of anti-competitive practices in the pharmaceutical industry.
- Damages Awarded: The jury determined that plaintiffs suffered nearly $885 million in damages, reflecting the severity of drug price manipulation and potentially leading to long-term negative implications for Takeda's financial health.
- Potential Market Reaction: This ruling may undermine investor confidence in Takeda, particularly against the backdrop of its ongoing cost-cutting initiatives and job cuts (4,500 positions), which could exacerbate concerns about its future profitability.
- Increased Regulatory Pressure: The outcome of this case may trigger stricter regulatory scrutiny, prompting other pharmaceutical companies to reassess their business strategies, especially regarding payment arrangements with generics, thereby impacting the competitive landscape of the entire industry.
See More
Investor Sentiment Cautious as Stock Markets Decline
- Weak Market Performance: Investor caution over Iran conflict risks, inflation concerns, and weaker Wall Street trends led the S&P 500 and Nasdaq to remain flat, while the Dow fell by 0.3%, indicating growing worries about economic outlook.
- European Economic Slowdown: European equities dropped by 0.8% due to rising energy prices and concerns over potential interest rate hikes by major central banks, with Euro area economic growth slowing to its weakest pace since mid-2024 in Q1 2026, reflecting the fragility of the recovery.
- Declining Risk Appetite in Asia-Pacific: Following the Beijing summit, investor risk appetite sharply cooled, with Chinese markets losing 1.6% and Japan's Nikkei 225 falling by 3%, highlighting the negative impact of geopolitical tensions on market sentiment.
- Disappointing Corporate Earnings: Tencent Holdings reported weaker-than-expected Q1 revenue and profit, while Alibaba missed fourth-quarter profit estimates, although executives noted strong returns from AI investments expected over the next three to five years, illustrating the challenges and opportunities faced by companies amid intensifying competition.
See More
Takeda to Cut 4,500 Jobs for Cost Savings
- Restructuring Plan: Takeda Pharmaceutical has announced plans to eliminate nearly 4,500 roles globally in fiscal 2026, aiming to generate up to ¥200 billion ($1.3 billion) in annual savings by FY28, demonstrating decisive action in response to market challenges.
- Financial Performance: In its fiscal 2025 financial disclosure, Takeda reported revenues of ¥4,505 billion ($28.5 billion) and earnings per share of ¥122 ($0.77), with a 3% year-over-year decline in revenue but a remarkable ~78% increase in EPS, reflecting the company's resilience in adversity.
- Restructuring Costs: The company expects to incur ¥170 billion ($1.1 billion) in restructuring costs in FY26, with lower amounts anticipated over the next two years, a strategy aimed at optimizing resource allocation and enhancing operational efficiency.
- Hiring Amid Layoffs: Although the layoffs represent less than 10% of the global workforce, Takeda indicated that it currently has approximately 2,200 job vacancies and will prioritize internal candidates for new hires, highlighting the company's commitment to talent development even while cutting costs.
See More
Takeda Pharmaceutical Shares Enter Oversold Territory
- Oversold Signal: Takeda Pharmaceutical (TAK) shares hit an RSI of 25.9 on Friday, indicating an oversold condition as the stock traded as low as $16.07 per share, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to seek entry points.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 72.1, TAK's low RSI could attract bullish investors, indicating potential for a market sentiment reversal and paving the way for future price rebounds.
- Historical Performance Analysis: TAK's 52-week low is $12.99 and high is $18.895, with the last trade at $16.25, demonstrating relative stability within its trading range, which may appeal to value-seeking buyers.
- Investor Sentiment: Despite the current oversold status, investors should carefully assess market sentiment and technical indicators to avoid making impulsive decisions in an uncertain market environment.
See More
Innovent's IBI363 Shows Survival Benefits in Lung Cancer Treatment
- Clinical Data Update: At the 2026 ASCO Annual Meeting, Innovent presented updated clinical data for its PD-1/IL-2α bispecific fusion protein IBI363, demonstrating a favorable long-term safety profile in immunotherapy-resistant non-small cell lung cancer (NSCLC), reinforcing its competitive edge in this area.
- Significant Survival Improvement: Among 67 squamous NSCLC patients without known EGFR mutations, the 3 mg/kg Q3W dose group achieved a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months, with a 24-month OS rate of 47.8%, highlighting IBI363's substantial survival advantage.
- Impact of Smoking History: In 58 EGFR wild-type adenocarcinoma patients, those with a smoking history had a median OS of 23.4 months, indicating that smoking history may significantly influence the efficacy of IBI363 in immunotherapy-resistant adenocarcinoma, further emphasizing its clinical potential.
- Favorable Safety Profile: In a long-term follow-up of 136 patients, IBI363 exhibited a treatment-emergent adverse event rate of 48.5%, primarily manageable arthralgia and anemia, with no new safety signals observed, indicating its viability for clinical use.
See More
Takeda Pharmaceutical Loses Antitrust Case Verdict
- Antitrust Verdict: A jury in the U.S. District Court for Massachusetts ruled against Takeda Pharmaceutical in the AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs approximately $884.9 million in single damages, highlighting the legal risks associated with drug patents and market competition.
- Treble Damages: Under U.S. antitrust law, the awarded damages are subject to automatic trebling, potentially increasing Takeda's liability to nearly $2.655 billion, which could severely impact its financial health and future cash flows.
- Post-Trial Actions: Takeda plans to vigorously pursue post-trial motions and an appeal, asserting that evidentiary and legal errors occurred during the trial, a strategy that may affect its market reputation and investor confidence.
- Financial Impact Assessment: The company is assessing the provision amount to be recognized in its full-year 2025 consolidated financial statements related to this matter and intends to revise and re-file its financial reports, although it does not expect a significant impact on its core financial results for 2025.
See More
Takeda Pharmaceutical Found Guilty of Delaying Generic Drug
- Anti-Competitive Ruling: A federal jury in Boston found Takeda Pharmaceutical (TAK) guilty of entering a reverse payment arrangement with generic drugmaker Par Pharmaceutical, resulting in health plans and pharmacies like CVS overpaying hundreds of millions, highlighting the direct consumer impact of anti-competitive practices in the pharmaceutical industry.
- Damages Awarded: The jury determined that plaintiffs suffered nearly $885 million in damages, reflecting the severity of drug price manipulation and potentially leading to long-term negative implications for Takeda's financial health.
- Potential Market Reaction: This ruling may undermine investor confidence in Takeda, particularly against the backdrop of its ongoing cost-cutting initiatives and job cuts (4,500 positions), which could exacerbate concerns about its future profitability.
- Increased Regulatory Pressure: The outcome of this case may trigger stricter regulatory scrutiny, prompting other pharmaceutical companies to reassess their business strategies, especially regarding payment arrangements with generics, thereby impacting the competitive landscape of the entire industry.
See More
Investor Sentiment Cautious as Stock Markets Decline
- Weak Market Performance: Investor caution over Iran conflict risks, inflation concerns, and weaker Wall Street trends led the S&P 500 and Nasdaq to remain flat, while the Dow fell by 0.3%, indicating growing worries about economic outlook.
- European Economic Slowdown: European equities dropped by 0.8% due to rising energy prices and concerns over potential interest rate hikes by major central banks, with Euro area economic growth slowing to its weakest pace since mid-2024 in Q1 2026, reflecting the fragility of the recovery.
- Declining Risk Appetite in Asia-Pacific: Following the Beijing summit, investor risk appetite sharply cooled, with Chinese markets losing 1.6% and Japan's Nikkei 225 falling by 3%, highlighting the negative impact of geopolitical tensions on market sentiment.
- Disappointing Corporate Earnings: Tencent Holdings reported weaker-than-expected Q1 revenue and profit, while Alibaba missed fourth-quarter profit estimates, although executives noted strong returns from AI investments expected over the next three to five years, illustrating the challenges and opportunities faced by companies amid intensifying competition.
See More
Takeda to Cut 4,500 Jobs for Cost Savings
- Restructuring Plan: Takeda Pharmaceutical has announced plans to eliminate nearly 4,500 roles globally in fiscal 2026, aiming to generate up to ¥200 billion ($1.3 billion) in annual savings by FY28, demonstrating decisive action in response to market challenges.
- Financial Performance: In its fiscal 2025 financial disclosure, Takeda reported revenues of ¥4,505 billion ($28.5 billion) and earnings per share of ¥122 ($0.77), with a 3% year-over-year decline in revenue but a remarkable ~78% increase in EPS, reflecting the company's resilience in adversity.
- Restructuring Costs: The company expects to incur ¥170 billion ($1.1 billion) in restructuring costs in FY26, with lower amounts anticipated over the next two years, a strategy aimed at optimizing resource allocation and enhancing operational efficiency.
- Hiring Amid Layoffs: Although the layoffs represent less than 10% of the global workforce, Takeda indicated that it currently has approximately 2,200 job vacancies and will prioritize internal candidates for new hires, highlighting the company's commitment to talent development even while cutting costs.
See More
